Cullinan Therapeutics, Inc. (CGEM)

Market Cap	469.27M
Revenue (ttm)	n/a
Net Income (ttm)	-167.38M
Shares Out	58.51M
EPS (ttm)	-3.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	233,195
Open	8.28
Previous Close	8.29
Day's Range	7.98 - 8.29
52-Week Range	7.90 - 30.19
Beta	-0.11
Analysts	Strong Buy
Price Target	32.86 (+309.73%)
Earnings Date	May 14, 2025

About CGEM

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 8, 2021
• Employees: 111
• Stock Exchange: NASDAQ
• Ticker Symbol: CGEM
• Website: https://cullinantherapeutics.com

Analyst Forecast

According to 8 analysts, the average rating for CGEM stock is "Strong Buy." The 12-month stock price forecast is $32.86, which is an increase of 309.73% from the latest price.

Price Target

$32.86

(309.73% upside)

Analyst Consensus: Strong Buy